Indaptus Therapeutics Inc
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency… Read more
Indaptus Therapeutics Inc (INDP) - Total Liabilities
Latest total liabilities as of September 2025: $2.23 Million USD
Based on the latest financial reports, Indaptus Therapeutics Inc (INDP) has total liabilities worth $2.23 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Indaptus Therapeutics Inc - Total Liabilities Trend (2008–2024)
This chart illustrates how Indaptus Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Indaptus Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Indaptus Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Integrated Media Technology Ltd
NASDAQ:IMTE
|
USA | $16.66 Million |
|
Prima Globalindo Logistik Tbk
JK:PPGL
|
Indonesia | Rp132.96 Billion |
|
Pucara Gold Ltd
PINK:PCRAF
|
USA | $96.20K |
|
SandRidge Mississippian Trust I
PINK:SDTTU
|
USA | $0.00 |
|
K.B. Recycling Industries Ltd
OTCQB:AKMYF
|
USA | $7.10 Million |
|
CARDINAL HEALTH
MU:CLH
|
Germany | €46.34 Billion |
|
Kim Hin Industry Bhd
KLSE:5371
|
Malaysia | RM104.34 Million |
Liability Composition Analysis (2008–2024)
This chart breaks down Indaptus Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Indaptus Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Indaptus Therapeutics Inc (2008–2024)
The table below shows the annual total liabilities of Indaptus Therapeutics Inc from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.39 Million | +19.19% |
| 2023-12-31 | $2.85 Million | -17.07% |
| 2022-12-31 | $3.43 Million | -26.59% |
| 2021-12-31 | $4.68 Million | +132.05% |
| 2020-12-31 | $2.02 Million | -79.32% |
| 2019-12-31 | $9.74 Million | +22.35% |
| 2018-12-31 | $7.96 Million | +38.59% |
| 2017-12-31 | $5.75 Million | +184.93% |
| 2016-12-31 | $2.02 Million | +22.59% |
| 2015-12-31 | $1.65 Million | -45.50% |
| 2014-12-31 | $3.02 Million | -31.16% |
| 2013-12-31 | $4.39 Million | +377.57% |
| 2012-12-31 | $918.23K | -28.80% |
| 2011-12-31 | $1.29 Million | +25.12% |
| 2010-12-31 | $1.03 Million | -40.06% |
| 2009-12-31 | $1.72 Million | -59.63% |
| 2008-12-31 | $4.26 Million | -- |